These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7996928)

  • 21. Azole-resistant oropharyngeal and esophageal candidiasis in patients with AIDS.
    Horn CA; Washburn RG; Givner LB; Peacock JE; Pegram PS
    AIDS; 1995 May; 9(5):533-4. PubMed ID: 7639986
    [No Abstract]   [Full Text] [Related]  

  • 22. Fluconazole for oropharyngeal candidiasis in anti-HIV positive haemophiliacs.
    Lim SG; Lee CA; Hales M; O'Doherty M; Winter M; Kernoff PB
    Aliment Pharmacol Ther; 1991 Apr; 5(2):199-205. PubMed ID: 1888820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients.
    Revankar SG; Dib OP; Kirkpatrick WR; McAtee RK; Fothergill AW; Rinaldi MG; Redding SW; Patterson TF
    Clin Infect Dis; 1998 Apr; 26(4):960-3. PubMed ID: 9564483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluconazole versus ketoconazole in the treatment of oropharyngeal candidiasis in HIV-infected children. Multicentre Study Group.
    Hernández-Sampelayo T
    Eur J Clin Microbiol Infect Dis; 1994 Apr; 13(4):340-4. PubMed ID: 8070443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis.
    Barchiesi F; Hollis RJ; Del Poeta M; McGough DA; Scalise G; Rinaldi MG; Pfaller MA
    Clin Infect Dis; 1995 Sep; 21(3):561-4. PubMed ID: 8527544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors.
    Hood S; Bonington A; Evans J; Denning D
    AIDS; 1998 Mar; 12(4):447-8. PubMed ID: 9520182
    [No Abstract]   [Full Text] [Related]  

  • 27. Fluconazole resistance in Candida in patients with AIDS--a therapeutic approach.
    Ng TT; Denning DW
    J Infect; 1993 Mar; 26(2):117-25. PubMed ID: 8473758
    [No Abstract]   [Full Text] [Related]  

  • 28. [For oral candidiasis and co. Fluconazole remains in the forefront].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():90. PubMed ID: 15373066
    [No Abstract]   [Full Text] [Related]  

  • 29. Candidiasis at ICAAC.
    Barr D; Smart T
    GMHC Treat Issues; 1995 Oct; 9(10):13. PubMed ID: 11362914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Geneva reports have implications for dental providers.
    Ritchie J
    Fac Notes (New Orleans La); 1998; 10(5):11-2. PubMed ID: 11365832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The treatment of oral candidiasis in a cohort of South African HIV/AIDS patients.
    Blignaut E; Botes ME; Nieman HL
    SADJ; 1999 Dec; 54(12):605-8. PubMed ID: 16892568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.
    Quereda C; Polanco AM; Giner C; Sánchez-Sousa A; Pereira E; Navas E; Fortún J; Guerrero A; Baquero F
    Eur J Clin Microbiol Infect Dis; 1996 Jan; 15(1):30-7. PubMed ID: 8641300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluconazole versus itraconazole in therapy of oropharyngeal candidiasis in cancer patients: a prospective comparative randomized trial.
    Studena V; Sycova Z; Helpianska L; Sorkovska D; Pichna P; Lacka J; Hlavacova E; Oravcova E; Krcmery V; Studena M
    J Chemother; 1995 Nov; 7 Suppl 4():204-5. PubMed ID: 8904157
    [No Abstract]   [Full Text] [Related]  

  • 34. Candidiasis.
    Powderly WG
    J Int Assoc Physicians AIDS Care; 1996 Oct; 2(10):36-9. PubMed ID: 11363911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Candidiasis in immune-compromised women.
    Cadman J
    GMHC Treat Issues; 1997; 11(7-8):18. PubMed ID: 11364644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Oral amphotericin B inefficacy in the treatment of fluconazole++ resistant oropharyngeal candidiasis in HIV-positive patients].
    Laguna F; Valencia E; Polo R; Moreno V; González-Lahoz JM
    Rev Clin Esp; 1996 Dec; 196(12):878-9. PubMed ID: 9132869
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of itraconazole and ketoconazole in HIV-positive patients with oropharyngeal or esophageal candidiasis. Human Immunodeficiency Virus Itraconazole Ketoconazole Project Group.
    de Repentigny L; Ratelle J
    Chemotherapy; 1996; 42(5):374-83. PubMed ID: 8874977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The diagnosis and treatment of candidiasis: current therapeutic options.
    Filler SG
    AIDS Patient Care STDS; 1997 Feb; 11 Suppl 1():S10-4; discussion S15. PubMed ID: 11361745
    [No Abstract]   [Full Text] [Related]  

  • 39. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues.
    Darouiche RO
    Clin Infect Dis; 1998 Feb; 26(2):259-72; quiz 273-4. PubMed ID: 9502438
    [No Abstract]   [Full Text] [Related]  

  • 40. Low levels of antigenic variability in fluconazole-susceptible and -resistant Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.
    Lopez-Ribot JL; McAtee RK; Kirkpatrick WR; La Valle R; Patterson TF
    Clin Diagn Lab Immunol; 1999 Sep; 6(5):665-70. PubMed ID: 10473514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.